Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
JOHNSON & JOHNSON
JNJ
Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including...
immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSE:JNJ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
•••
Trevor Abes
X
Post by
Trevor Abes
on Dec 04, 2024 4:31pm
Buzz on the Bullboards: Tangible growth stocks
This week, Canada’s main stock index, the TSX, hit a record high thanks to gains in technology and bank stocks.
read article.
(32)
•••
SmartBull65
X
Post by
SmartBull65
on Dec 03, 2024 3:41pm
JNJ: Strong Pharma Growth, But Legal Risks Remain ⚠️
JNJ’s pharma division is crushing it, with big hits like Imbruvica and Darzalex driving revenue. But the ongoing legal battles—especially with talc and opioids—are still a worry. Overall, long-term
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 02, 2024 8:00am
New Press Release - Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis SPRING HOUSE, Pa., Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S...
read article.
(8)
•••
WealthLine48
X
Post by
WealthLine48
on Nov 26, 2024 7:14pm
$JNJ Steady but Slow: Where’s the Spark?
Johnson & Johnson ($JNJ) is a safe, steady name but lacks growth oomph. Diagnostic biotech firms, like MYNZ, bring the innovation spark, pioneering new testing methods that could redefine how
...more
(32)
•••
SmartBull65
X
Post by
SmartBull65
on Nov 24, 2024 12:33pm
JNJ's Flatline: Buy Opportunity?
I’ve been watching JNJ, and despite its steady dividends, the stock is stuck around $155. Promising drug trials like their psoriasis treatment could boost it if FDA approvals come through. Regulatory
...more
(2)
•••
TradeDriver718
X
Post by
TradeDriver718
on Nov 22, 2024 8:57am
Is $JNJ Ready to Bounce Back?
Just checked the chart on $JNJ—looks like it’s been consolidating for a minute. Could see a reversal soon if support holds at $152. Also watching MYNZ; hearing it might take off. Anyone loading up
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Jul 17, 2024 3:17pm
Johnson & Johnson Announces Quarterly Dividend for Third Qua
Just In: $JNJ Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024Johnson @ Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the
...more
(567)
•••
BSdetector2016
X
Post by
BSdetector2016
on Apr 05, 2024 12:55pm
Will this ever turn around?
EOM.
(1)
•••
TechTitan
X
Comment by
TechTitan
on Oct 06, 2023 1:38pm
RE:A BIG DAY for us
looks like like S&P could turn around and help J&J
(29)
•••
StockAlchemy
X
Post by
StockAlchemy
on Jul 20, 2023 10:52am
A BIG DAY for us
Earnings report for us today.
(2010)
•••
scottrose
X
Post by
scottrose
on Jul 06, 2023 9:36am
Starting slow
Jumped in on this a while back and so far the decision to hold is one I don't regret.
(3)
•••
Richardson35
X
Post by
Richardson35
on Apr 13, 2023 3:21am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(319)
•••
jimsenior
X
Post by
jimsenior
on Jan 23, 2023 9:56am
Aveeno
Until recently Aveeno daily moisturizing lotion was using Canadian oats. They no longer mention Canadian oats on their bottle. I have contacted the company in re this matter. and have not
...more
(0)
•••
robertsmith02
X
Post by
robertsmith02
on Aug 23, 2022 4:15am
Ophthalmic Lasers Market to Grow at 5.07% CAGR by 2027
The latest research study, "Ophthalmic Lasers Market: Global Industry Trends, Size, Growth, Opportunity and Forecast 2022-2027" has been added by IMARC Group. The global ophthalmic
...more
(1)
•••
edwardebreen15
X
Post by
edwardebreen15
on Aug 22, 2022 8:45am
Point-of-Care Diagnostics Market Size and Share 2021-2026
According to IMARC Group’s latest report, titled “Point-of-Care Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global market reached a strong
...more
(3)
•••
Richardson35
X
Post by
Richardson35
on Jul 15, 2022 9:00pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities